To include your compound in the COVID-19 Resource Center, submit it here.

Regeneron falls on atopic dermatitis data for AbbVie's upadacitinib

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) lost $28.30 to $471.92 on Thursday and shed more than $2.9 billion in market cap after AbbVie Inc. (NYSE:ABBV) reported that its atopic dermatitis candidate upadacitinib (ABT-494)

Read the full 316 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE